睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌IV期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由中国科学技术大学附属第一医院(安徽省立医院)牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方中国科学技术大学附属第一医院(安徽省立医院)First Affiliated Hospital of USTC合肥医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07150624,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Child-Pugh grade A or B, with a score of ≤ 7; ASA grades I to III.

    入选标准第 5 条

  3. No history of portal vein embolization prior to enrollment. If TACE treatment was previously received, it must have been completed > 6 months ago; if systemic anti-tumor drug therapy was previously received, it must have been completed > 4 weeks ago.

    入选标准第 9 条

  4. Preoperative ALT < 2x ULN (upper limit of normal).

    入选标准第 8 条

  5. Pregnant and lactating women

    排除标准第 14 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;日常活动能力;影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07150624,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Diagnosed as HCC through imaging and laboratory tests, and capable of undergoing laparoscopic anatomical resection.
  2. Surgical scope (defined by randomization stratification):Stratum 1: Major hepatectomy, involving the resection of at least 3 Couinaud liver segments, including right hemihepatectomy and extended right hemihepatectomy, etc.Stratum 2: Minor hepatectomy, involving the resection of no more than 2 Couinaud liver segments. This includes right posterior sectorectomy, right anterior sectorectomy, left lateral sectionectomy, single segmentectomy, etc.
  3. During the operation, the Pringle method is used to block the first hepatic portal. Each block lasts ≤ 15 minutes, and the blocking procedure is performed 2 to 4 times.
  4. Age: 18 - 80 years old. Gender: Open to both male and female. Body Mass Index (BMI): 18.5 - 28 kg/m².
  5. Child-Pugh grade A or B, with a score of ≤ 7; ASA grades I to III.
  6. Preoperative ICG R15 < 10%, and the residual liver volume/standard liver volume > 40%.
  7. A single HCC (hepatocellular carcinoma), with a tumor diameter of less than 10 cm, without distant metastasis or invasion of the portal vein system.
  8. Preoperative ALT < 2x ULN (upper limit of normal).
  9. No history of portal vein embolization prior to enrollment. If TACE treatment was previously received, it must have been completed > 6 months ago; if systemic anti-tumor drug therapy was previously received, it must have been completed > 4 weeks ago.
  10. No liver-damaging treatment drugs were used within two weeks prior to enrollment.

排除标准:Exclusion Criteria:

  1. Reserve liver vascular damage, including: reconstruction after severance, ligation, embolization, thrombosis, etc
  2. Combined with abnormal coagulation function (prothrombin time prolonged by more than 3 seconds)
  3. Combining obstructive jaundice, severe heart disease, severe kidney disease and other serious illnesses
  4. During the operation, microwave treatment or a combination of microwave treatment was adopted
  5. More than 4 times of blocking at the first hepatic hilum, or a single blocking duration longer than 15 minutes
  6. Non-anatomic liver resection, where the remaining liver contains large areas of ischemic/edematous regions
  7. More than 1000ml of blood transfusion during the operation
  8. During the operation, an extra-hepatic disease was discovered. Other organs except the gallbladder needed to be removed simultaneously
  9. During the operation, other intrahepatic lesions were discovered, which required combination with other surgeries, such as ablation or choledochojejunostomy
  10. Diseases that have previously received systemic treatment with glucocorticoids, such as chronic kidney disease, inflammatory diseases, or other immune system-related disorders
  11. Psychosis, severe neurosis, those who cannot cooperate with this experiment
  12. Participated in other clinical trials within the previous 3 months before enrollment
  13. Allergy or intolerance to benzoic acid, or to the study drug
  14. Pregnant and lactating women
  15. The researchers believe that any participants who have any other factors that would make them unsuitable for this trial should not be included

引自 ClinicalTrials.gov, NCT07150624, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07150624,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07150624